Tag: Non-feminizing estradiol stereoisomer

  • 17-alpha-Estradiol

    Non-feminizing endogenous estradiol stereoisomer with 5-alpha-reductase inhibitory activity and lifespan-extending properties

    A naturally occurring 17-alpha-epimer of estradiol with approximately 100-fold reduced classical estrogen receptor affinity, topical registration as alfatradiol for androgenetic alopecia, and reproducible male-specific lifespan extension in the NIA Interventions Testing Program, mediated through estrogen receptor alpha signaling in the hypothalamus and liver.

    Abstract

    17-alpha-Estradiol (estra-1,3,5(10)-triene-3,17-alpha-diol; CAS 57-91-0; alfatradiol; molecular formula C18H24O2; molecular weight 272.39 g/mol) is the 17-alpha-stereoisomer of the principal mammalian estrogen 17-beta-estradiol, distinguished solely by the axial (alpha) orientation of the hydroxyl group at carbon 17 of the steroid D-ring. The compound occurs endogenously at low concentrations in mammalian brain and peripheral tissues and has been characterized since the 1950s as a weak estrogen with approximately 100-fold lower binding affinity for the classical nuclear estrogen receptors ER-alpha and ER-beta relative to the 17-beta-epimer [1, 2]. Despite this reduced receptor engagement, 17-alpha-estradiol retains potent estrogen receptor-independent antioxidant activity equivalent to 17-beta-estradiol in lipid peroxidation assays and neuroprotection models [3, 4], inhibits 5-alpha-reductase and aromatase in skin and hair follicle tissue (the basis for its topical registration as alfatradiol in several European jurisdictions for androgenetic alopecia) [5, 6], and has emerged as one of the most robustly validated lifespan-extending compounds in the National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse longevity screening platform.

    The ITP demonstrated that dietary 17-alpha-estradiol at 14.4 parts per million (approximately 2 mg/kg/day mouse-equivalent) extended median lifespan by approximately 19 percent in male UM-HET3 mice when initiated at 16 months of age and by approximately 11 percent when initiated at 20 months, with no lifespan extension observed in female mice at any initiation age [7, 8, 9]. The male specificity of the lifespan effect has been replicated across three independent ITP sites (the Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center) and is among the largest and most reproducible lifespan extensions reported in the ITP, comparable in magnitude to acarbose and exceeded only by rapamycin. The sex-specific pattern has driven substantial mechanistic investigation. Stout et al. (2017) demonstrated that 17-alpha-estradiol alleviates age-related metabolic and inflammatory dysfunction in male mice without inducing feminization, with treated males showing reduced fasting glucose, reduced fasting insulin, reduced glycosylated hemoglobin, reduced visceral adiposity, reduced circulating and adipose tissue pro-inflammatory cytokines, and increased AMP-activated protein kinase activity in visceral adipose tissue [10]. Steyn et al. (2018) established that 17-alpha-estradiol acts through hypothalamic pro-opiomelanocortin (POMC) expressing neurons to reduce feeding behavior, with near-complete loss of the anorectic response in POMC-neuron-ablated mice [11]. Mann et al. (2020) demonstrated through liver-specific and global ER-alpha knockout models that the metabolic health benefits of 17-alpha-estradiol (reductions in fasting insulin, HbA1c, glucose intolerance, and visceral adiposity) are mediated through estrogen receptor alpha, resolving prior uncertainty about whether a non-classical receptor was responsible [12]. Garratt et al. (2017, 2018) reported that males, but not females, metabolize 17-alpha-estradiol into one or more estriol derivatives, and that the sex-specific beneficial effects may depend on a downstream metabolite rather than on the parent compound [13, 14].

    The compound has limited human clinical data. Topical formulations (alfatradiol 0.025 percent solution, marketed as Ell-Cranell alpha) are registered in Germany, Austria, and several other European jurisdictions for androgenetic alopecia in men and women, with demonstrated stabilization of hair loss through local 5-alpha-reductase inhibition and aromatase induction [5, 6]. No clinical trials of oral 17-alpha-estradiol for longevity, metabolic, or neuroprotective endpoints have been completed or registered in humans as of the monograph revision date.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.